Skip to content

Inspection Record

LCC Ltd. — FDA 483 Findings

US FDAInspected 2024-03-22Published 2026-10-20 11 findingsStability and storageProcess validationLaboratory and QC controlsQuality unit oversightMaterial and supplier controlDocumentation and recordsEquipment and facilityTraining and personnelComplaint and recall handling

Inspectors Arsen Karapetyan · Brittny C CargoThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Stability and storage

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

2Process validation

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product.

3Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

4Quality unit oversight

The quality control unit lacks responsibility to approve all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

5Material and supplier control

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

6Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

7Equipment and facility

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design, of adequate size and suitably located to facilitate operations for its intended use and cleaning and maintenance.

8Material and supplier control

Records associated with drug product components, production, control and distribution and within the retention period for such records, were not made readily available for authorized inspection.

9Equipment and facility

Procedures for the cleaning and maintenance of equipment are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembling equipment as necessary to assure proper cleaning and maintenance.

10Training and personnel

Individuals responsible for supervising the manufacture, processing, packing and holding of a drug product lack the education, training and experience to perform their assigned functions in such a manner as to assure the drug product has the safety, identity, strength, quality and purity that it purports or is represented to possess.

11Complaint and recall handling

Complaint records are deficient in that they do not include the findings of the investigation and follow- up.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

LCC Ltd. findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.